logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12221426 B1

PDFFull Text
Date of Patent:
Feb. 11, 2025

Filed:

Aug. 29, 2019

Inhibitory material against human body-derived nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like, and anticancer agent comprising same as effective ingredient or pharmaceutical composition comprising same as effective ingredient for treatment of hyperlipidemia

Applicants:

Seoul National University R&db Foundation, Seoul, KR;

Korea Research Institute of Chemical Technology, Daejeon, KR;

National Cancer Center, Gyeonggi-do, KR;

Inventors:

Bong-Jin Lee, Seoul, KR;

Kyu-Yeon Lee, Seoul, KR;

Sang Jae Lee, Seoul, KR;

Dong-Gyun Kim, Seoul, KR;

Joo Youn Lee, Daejeon, KR;

Kwan-Young Jeong, Daejeon, KR;

Heui Cherl Yang, Daejeon, KR;

Hyeon-Kyu Lee, Daejeon, KR;

Hyoun Sook Kim, Gyeonggi-do, KR;

Assignees:

Seoul National University R&DBFoundation, Seoul, KR;

Korea Research Institute of Chemical Technology, Daejeon, KR;

National Cancer Center, Gyeonggi-do, KR;

Attorney:

Licata & Tyrell P.C.

Primary Examiner:

Bruck Kifle

Assistant Examiner:

Kevin S Martin

Int. Cl.
CPC ...
C07D 277/32 (2006.01); A61P 3/06 (2006.01); A61P 35/00 (2006.01); A61K 31/426 (2006.01);
U.S. Cl.
CPC ...
C07D 277/32 (2013.01); A61P 3/06 (2018.01); A61P 35/00 (2018.01);
Abstract

A nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like (NSDHL) inhibitor provided according to an aspect of the present invention can be used not only as an anticancer agent capable of overcoming resistance to EGFR-targeting anticancer agents, but also advantageously in the treatment of hyperlipidemia.

Find Patent Forward Citations

Quick Actions:

Lee, Bong-Jin. (2025). Inhibitory material against human body-derived nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like, and anticancer agent comprising same as effective ingredient or pharmaceutical composition comprising same as effective ingredient for treatment of hyperlipidemia (U.S. Patent No. 12221426). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12221426

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…